Wong JYC, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA:  A Phase I Trial of Y-90-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biother Radiopharm. 21:88, 2006.

Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JYC, Raubitschek A, Shively JE: Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA Diabody. Bioconjugate Chem. 17:68, 2006.

Kenanova, V., Olafsen, T., Crow, D.M., Sundaresan, G., Subbarayan, M., Carter, N.H., Ikle, D.N., Yazaki, P.J., Chatziioannou, A.F., Gambhir, S.S.,Williams, L.E., Shively, J.E., Colcher, D., Raubitschek, A. A., and Wu, A.M. Tailoring the pharmacokinetics of engineered antibody fragments.Biodistribution and small animal PET imaging studies of anti-CEA scFv-Fc and variants. Cancer Research 65(2):622-631, 2005.

Yazaki, P.J., Sherman, M.A., Shivley, J.E., Ikle, D.,Williams, L.E.,  Wong, J.Y.C., Colcher, D., Wu, A.M., and Raubitschek. Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Engineering Design & Selection 17 (5), 481-489, 2004.

Olafsen, T., Tan, G.J., Cheung, C., Yazaki, P.J., Park, J.M., Shivley, J.E., Williams, L.E., Raubitschek, A.A., Press, M.F., and Wu, A.M. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Engineering Design & Selection, 17, 315-323, 2004.

Wong, J.Y.C., Chu, D.Z., Williams, L.E., Yamauchi, D.M., Ikle, D. N., Kwok, C.S., Liu, A., Wilczynski, S., Colcher, D., Yazaki, P.J., Shively, J.E., Wu, A.M., and Raubitschek, A.A.. A pilot trial evaluating a 123I labeled 80 kD engineered anti-CEA antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clinical Cancer Research, 10, 5014-5021, 2004.

Sundaresan, G., Olafsen, T., Yazaki, P.J., Shivley, J.E., Finn, R.D., Larson, S.M., Raubitschek, A.A., Williams, L.E., Chatziioannou, A.F., Gambhir, and Wu, A.M. 124I-labeled engineered anti-CEA Minibodies and diabodies allow high-contrast, antigen specific amall-animal PET imaging of xenografts in athymic mice. Journal of Nuclear Medicine 44, 1962-1969, 2003.

Olafsen, T., Cheung, C., Yazaki, P.J., Li, L., Sundaresan, G., Gambhir, S.S., Sherman, M.A., Williams, L.E., Shivley, J.E., Raubitschek, A.A., Wu, A.M. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Engineering Design & Selection 17, 21-27, 2004.

Williams L, Liu A, Wu A, Yamauchi D, Lopatin G, Yazaki P, Raubitschek A, Wong J. Verification of Imaging Figure of Merit as a Predictor of Tumor Imaging Clarity. Proceedings of the World Congress on Medical Physics and Biomedical Engineering, Sydney, Australia, [CD-ROM] ISBN 1877040142, Paper No. 737, 2003.

Wong, J.Y.C., Shibata, S., Williams, L.E., Kwok, C.S., Liu, A., Chu., D.Z., Yamauchi, D.M., Wilczynski, S., Ikle, D.N., Wu, A.M., Yazaki, P.J., Shivley, J.E., Doroshow, J.H., Raubitschek, A.A. A Phase I Trial of 90Y-anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research 5842 Vol. 9, 5842-5852, 2003.

Yazaki, P. J., and Wu, A.M. Expression of recombinant antibodies in mammalian cell lines. In:  Methods in Molecular Biology: Antibody Engineering Methods and Protocols, (B. Lo, ed.), Humana Press, Totowa, NJ, 248: 255-225, 2003.

Carmicheal, J.A., Power, B.E., Garrett, T.P.J., Yazaki, P.J., Shively, J. E., Raubitschek, A.A., Wu, A.M. and Hudson, P.J.  The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFv in VL to VH orientation resolved to 2.6 A:  Implications for diabody flexibility.  J. Mol. Biol., 326, 341-351, 2003.

Williams, L.e., Wu, A.M., Yazaki, P.J., Liu, A., Yamauchi, D.M., Shively, J.E., Raubitschek, A.A. and Wong, J.Y.C.  Methods to select proteins and antibodies for clinical trials.  Cancer Biother. Radiopharm., 17, 484-485, 2002.

Yazaki, P.J., Shively, L., Clark, C., Cheung, C.-W., Le, W., Szpikowska, B., Shively, J.E., Raubitschek, A.A. and Wu, A.M.  Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.  J. Immunol. Methods, 253,195-208, 2001.

Williams, L.E., Wu, A.M., Yazaki, P.J., Liu, A., Raubitschek, A.A., Shively, J.E. and Wong, J.Y.C.  Numerical selection of optimal tumor imaging agents with application to engineered antibodies.  Cancer Biother. Radiopharm. 16, 25-35, 2001.

Yazaki, P.J., Wu, A.M., Tsai, S.w., Williams, L.E., Ikle, D.N., Wong, J.Y., Shively, J.E. and Raubitschek, A.A.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody:  Comparison to radioiodinated fragments.  Bioconjugate Chemistry 12, 220-228, 2001.

Wu, A.M. and Yazaki, P.J.  Designer genes:  Recombinant antibody fragments for biological imaging.  Quarterly Journal of Nuclear Medicine 44, 268-283, 2000.

Williams, L.E., Liu, A., Wu, A.M., Yazaki, P.J., Yamauchi, D.M., Lopatin, G., Raubitschek, A.A., and Wong, J.Y.C. Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.  Med. Phys. 27, 988-994, 2000.

Wu, A.M., Yazaki, P.J., Tsai, S., Nguyen, K., Anderson, A-L., McCarthy, D.W., Welch, M.J., Shively, J.E., Williams, L.E., Raubitschek, A.A., Wong, J.Y., Tokokuni, T., Phelps, M.E., and Gambhir, S.S.  High-resolution microPET imaging of carcinoembryonic antigen positive xenografts using a copper-64 labeled engineered antibody fragment. PNAS 97, 8495-8500, 2000.

Shih, C.C., Hu, M.C.T., Hu, J., Yazaki, P.J., Weng, Y., Medeiros J. and Forman, S.J.  A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells.  Blood 95, 1957-1966, 2000.

Yazaki, P.J., and Wu, A.M., Construction and characterization of minibodies for imaging and therapy of colorectal cancer. Clinical Cancer Research, 10, 3224s-3231s, 1999.

Wong, J.Y.C., Somlo, G., Odom-Maryon, T., Williams, L.E., Liu, A., Yamauchi, D., Wu, A.M., Yazaki, P. , Wilczynski, S., Shively, J.E., Forman, S., Doroshow, J.H. and Raubitschek, A.A.  Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell in patients with carcinoembryonic antigen-producing metastatic breast cancer.  Clin. Canc. Res. 5, 3224-3231, 1999.

You, Y.H., Hefta, L.J., Yazaki, P.J., Wu, A.M. and Shively, J.E.  Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in Pichia pastoris.  Anticancer Res.  18, 3193-3202, 1998.

Cunningham, H.B., Yazaki, P.J., Oades, K., Domingo, R., Sabbadini, R.A. and Dahms, A.S.  The skeletal muscle transverse tubular Mg-ATPase:  Identity with Mg-ATPases of smooth muscle and brain.  Arch. Biochem.  303, 42-43, 1993.

Yazaki, P.J.  Structural studies of two proteins of the skeletal muscle triadic complex. Calsequestrin and the Mg-ATPase.  Ph.D., dissertation, 1992.

Yazaki, P.J., Cunningham, H.B., Kang, J.J., Jachec, C., Hunt, S.A., Domingo, R.C. and Dahms, A.S.  Characterization of a muscle membrane ATPase glycoprotein.  In:  Advances in Experimental Medical Biology, Plenum Publishing Corp., NY  (311), pp. 425-426, 1992.

Yazaki, P.J., Salvatori, S. and Dahms, A.S.  Amino acid sequence of chicken calsequestrin deduced from cDNA: Comparison of calsequestrin and aspartactin.  Biochem. Biophys. Res. Comm.  170, 1089-1095, 1990.

Yazaki, P.J., Salvatori, S., Sabbadini, R.A. and Dahms, A.S.  Calsequestrin, an intracellular calcium-binding protein of skeletal muscle sarcoplasmic reticulum, is homologous to aspartactin, a putative laminin-binding protein of the extracellular matrix.  Biochem. Biophys. Res. Comm.  166, 898-903, 1990.

Richman, D.D., Hostetler, K.Y., Yazaki, P.J. and Clark, S.  Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine.  Virology   152, 200-210, 1986.

Hostetler, K.Y., Reasor, M.J., Walker, E.R., Yazaki, P.J. and Frazee,  B.W.  Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats.  Biochim. Biophys. Acta, 875, 400-405, 1986.

Hostetler, K.Y., Reasor, M.J. and Yazaki, P.J.  Chloroquine-induced phospholipid fatty liver, measurement of drug and lipid concentration in rat liver lysosomes.  J. Biol. Chem.  260, 215-219, 1985.

Pappu, A.S.,  Yazaki, P.J. and Hostetler, K.Y.  Inhibition of purified lysosomal phospholipase A1 by beta-adrenoreceptor blockers.  Biochem. Pharmacol.  34, 521-524, 1985.

Hostetler, K.Y., Yazaki, P.J. and van den Bosch, H.  Purification of lysosomal phospholipase A, evidence for multiple isoenzymes in rat liver.  J. Biol. Chem.  257, 13367-13373, 1982.

Richman, D.D., Yazaki, P.J. and Hostetler, K.Y.  The intracellular distribution and antiviral activity of amantadine.  Virology  112, 81-90, 1980.

Hostetler, K.Y. and Yazaki, P.J.  Deficiency of carnitine palmitoyltransferase in transformed lymphoblasts from a patient having a deficiency of carnitine palmitoyltransferase in skeletal muscle.  Biochem. Biophys. Res. Comm. 94, 270-277, 1980.

Hostetler, K.Y. and Yazaki, P.J.  The subcellular localization of neutral sphingomyelinase in rat liver.  J. Lipid Res.   20, 456-463, 1976.

Poorthuis, B.M.H.M., Yazaki, P.J. and Hostetler, K.Y.  An improved two-dimensional thin-layer chromatography system for the separation of phosphatidyglycerol and its derivatives.  J. Lipid Res.  17, 433-437, 1976.

This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 06/08